A Phase Ia Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of BR101 Injection, as a Single Agent in Subjects With Advanced Solid Tumors
Latest Information Update: 25 Sep 2023
At a glance
- Drugs BR 101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors BioRay Pharmaceutical
- 25 Aug 2023 New trial record